This article was originally published in The Rose Sheet
Executive SummarySkin care sales up 8% in North America in third quarter due to strong sales of Dove and Suave bar soaps and Dove facial cloths, according to Unilever sales and earnings announcement Nov. 2. Consolidated personal care sales increased 9% during the quarter, led by Dove including introduction of Dove shampoo in Italy and Japan, Unilever states. Mass market gains were partially offset by decline in prestige fragrances. Firm lost approximately $54.3 mil. (€1=$.90) in prestige fragrance category in third quarter due to decline in consumer confidence, Unilever says. Ad support will continue for Nautica, BCBG and Truth, which are expected to drive growth. Total turnover for Q3 increased 13% to $12.27 bil., while net profit before exceptional items, amortization of goodwill and intangibles was up 5% to $952.3 mil...
You may also be interested in...
Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.
Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.